Author:
Thambisetty Madhav,Howard Robert
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology (clinical)
Reference10 articles.
1. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2212948 (2022).
2. Ackley, S. F. et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 372, n156 (2021).
3. Gleason, A., Ayton, S. & Bush, A. I. Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer’s clinical trials. Eur. J. Neurol. 28, e1 (2021).
4. Center for Drug Evaluation and Research. Aduhelm (aducanumab) FDA statistical review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000StatR.pdf (2021).
5. Andrews, J. S. et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement. (N.Y.) 5, 354–363 (2019).
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献